Arrowhead Pharmaceuticals (ARWR) has received approval from the Chinese National Medical Products Administration for its drug, Redemplo. This approval specifically targets the use of Redemplo to lower triglyceride levels in adult patients diagnosed with familial chylomicronemia syndrome. This development marks a significant step for Arrowhead in expanding its presence in the Chinese pharmaceutical market.
https://www.gurufocus.com/news/4099476/arrowhead-arwr-gains-approval-in-china-for-redemplo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.